Human immunodeficiency virus type 1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with decline in CD4 cells, progression to AIDS, and survival: Comparison with viral RNA measurement

Journal of Infectious Diseases

Volumn 181, Issue 4, 2000, Pages 1280-1288

  Ledergerber, Bruno ^a   Flepp, Markus ^a   Böni, Jürg ^b   Tomasik, Zuzana ^b   Cone, Richard W ^a   Lüthy, Ruedi ^a,c   Schüpbach, Jörg ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c KLINIK IM PARK   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; SURVIVAL; T LYMPHOCYTE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAT; HIV CORE PROTEIN P24; HIV-1; HUMANS; MALE; PROTEIN DENATURATION; RISK FACTORS; RNA, VIRAL; SURVIVAL RATE; VIRAL LOAD;

EID: 0034024945     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315366     Document Type: Article

References (37)

1. 1. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362:355-8.
2. 2. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362:359-62.
3. 3. Haase AT, Henry K, Zupancic M, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996; 274:985-9.
4. 4. Piatak M Jr, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259: 1749-54.
5. 5. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-22.
6. 6. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-6.
7. 7. Cao Y, Ho DD, Todd J, et al. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses 1995; 11:353-61.
8. 8. Henrard DR, Daar E, Farzadegan H, et al. Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9:305-10.
9. 9. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122:573-9.
10. 10. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-70.
11. 11. Loveday C, Kaye S, Tenant-Flowers M, et al. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 1995; 345:820-4.
12. 12. Hammer SM. Advances in antiretroviral therapy and viral load monitoring. AIDS 1996; 10:S1-11.
13. 13. Schupbach J, Boni J. Quantitative and sensitive detection of immune-complexed and free HIV antigen after boiling of serum. J Virol Methods 1993; 43:247-56 (erratum: J Virol Methods 1993; 45:245).
14. 14. Schupbach J, Boni J, Tomasik Z, Jendis J, Seger R, Kind C. Sensitive detection and early prognostic significance of p24 antigen in heat-denatured plasma of human immunodeficiency virus type 1-infected infants. Swiss Neonatal HIV Study Group. J Infect Dis 1994; 170:318-24.
15. 15. Schupbach J, Flepp M, Pontelli D, Tomasik Z, Luthy R, Boni J. Heat-mediated immune complex dissociation and enzyme-linked immunosorbent assay signal amplification render p24 antigen detection in plasma as sensitive as HIV-1 RNA detection by polymerase chain reaction. AIDS 1996; 10:1085-90.
16. 16. Lyamuya E, Bredberg-Raden U, Massawe A, et al. Performance of a modified HIV-I p24 antigen assay for early diagnosis of HIV-1 infection in infants and prediction of mother-to-infant transmission of HTV-1 in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12: 421-6.
17. 17. Boni J, Opravil M, Tomasik Z, et al. Simple monitoring of antiretroviral therapy with a signal-amplification-boosted HIV-1 P24 antigen assay with heat-denatured plasma. AIDS 1997; 11:F47-52.
18. 18. Nadal D, Böni J, Kind C, et al. Prospective evaluation of amplification-boosted ELISA for heat-denatured p24 antigen for diagnosis and monitoring of pediatric HIV-1 infection. J Infect Dis 1999; 180:1089-95.
19. 19. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315:1194-9.
20. 20. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999; 340:1301-6.
21. 21. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353:863-8.
22. 22. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41(RR-17):1-19.
23. 23. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982; 69:239-41.
24. + T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 1997; 11:1799-806.
25. 25. Craib KJ, Strathdee SA, Hogg RS, et al. Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection. J Infect Dis 1997; 176:798-800.
26. 26. Wong MT, Dolan MJ, Kozlow E, et al. Patterns of virus burden and T cell phenotype are established early and are correlated with the rate of disease progression in human immunodeficiency virus type 1-infected persons. J Infect Dis 1996; 173:877-87.
27. + lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996; 334:426-31.
28. 1 (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis 1998; 177:617-24.
29. 29. Spijkerman IJ, Prins M, Goudsmit J, et al. Early and late HIV-1 RNA level and its association with other markers and disease progression in long-term AIDS-free homosexual men. AIDS 1997; 11:1383-8.
30. 30. Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis 1996; 174:704-12.
31. 31. Galetto-Lacour A, Yerly S, Perneger TV, Baumberger C, Hirschel B, Perrin L. Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. Swiss HIV Cohort Study Group. J Infect Dis 1996; 173:1388-93.
32. + cell counts in HIV-infected patients. Swiss HIV Cohort Study. Arch Intern Med 1998; 158:247-52.
33. 33. Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA 1995; 274:554-8.
34. 34. Farzadegan H, Henrard DR, Kleeberger CA, et al. Virologic and serologic markers of rapid progression to AIDS after HIV-1 seroconversion. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13:448-55.
35. 35. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993; 262:1011-8.
36. 36. Pantaleo G, Cohen OJ, Schacker T, et al. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection implications for antiviral therapy. Nat Med 1998; 4:341-5.
37. 37. Zhang LQ, Dailey PJ, He T, et al. Rapid clearance of simian immunodeficiency virus particles from plasma of rhesus macaques. J Virol 1999; 73: 855-60.